Cellular Therapy Using Epitope-Imprinted Composite Nanoparticles to Remove α-Synuclein from an In Vitro Model.
Mei-Hwa LeeJeng-Shiung JanJames L ThomasYuan-Pin ShihJin-An LiChien-Yu LinTooru OoyaLilla BarnaMária MészárosAndrás HarazinGergő PorkolábSzilvia VeszelkaMária A DeliHung-Yin LinPublished in: Cells (2022)
Several degenerative disorders of the central nervous system, including Parkinson's disease (PD), are related to the pathological aggregation of proteins. Antibodies against toxic disease proteins, such as α-synuclein (SNCA), are therefore being developed as possible therapeutics. In this work, one peptide (YVGSKTKEGVVHGVA) from SNCA was used as the epitope to construct magnetic molecularly imprinted composite nanoparticles (MMIPs). These composite nanoparticles were characterized by dynamic light scattering (DLS), high-performance liquid chromatography (HPLC), isothermal titration calorimetry (ITC), Brunauer-Emmett-Teller (BET) analysis, and superconducting quantum interference device (SQUID) analysis. Finally, the viability of brain endothelial cells that were treated with MMIPs was measured, and the extraction of SNCA from CRISPR/dCas9a-activated HEK293T cells from the in vitro model system was demonstrated for the therapeutic application of MMIPs.
Keyphrases
- solid phase extraction
- molecularly imprinted
- high performance liquid chromatography
- simultaneous determination
- endothelial cells
- tandem mass spectrometry
- mass spectrometry
- ms ms
- molecular dynamics
- small molecule
- liquid chromatography
- crispr cas
- white matter
- mesenchymal stem cells
- bone marrow
- cerebrospinal fluid
- resting state
- quantum dots
- newly diagnosed
- vascular endothelial growth factor
- smoking cessation
- cerebral ischemia